Crystalline deposits in the macula - tamoxifen maculopathy or macular telangiectasia?
| Autor: | Rijal RK; Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Pondicherry, 605007 India., Nakhwa C, Sindal MD |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH [Nepal J Ophthalmol] 2014 Jul-Dec; Vol. 6 (2), pp. 227-9. |
| DOI: | 10.3126/nepjoph.v6i2.11713 |
| Abstrakt: | Introduction: Tamoxifen citrate is an anti-estrogen agent used in the treatment of breast carcinoma. Crystalline maculopathy is a rare complication of tamoxifen therapy. The clinical picture resembles that of idiopathic macular telangiectasia (IMT) Type 2, which is a more common clinical entity. Objective: To report a case of crystalline maculopathy secondary to tamoxifen and highlight the importance of the medical history and investigations in differentiating it from IMT Type 2. Case: A diabetic female with a past history of breast carcinoma treated with tamoxifen came to the hospital for a routine eye check-up. Crystalline deposits were seen in the parafoveal region in both the eyes.The spectral domain optical coherence tomography (SD-OCT) showed foveal cysts in the inner retinal layer and fundus autofluorescence (FAF) and fundus fluorescein angiography (FFA) were within normal limits. Conclusion: While tamoxifen maculopathy is reversible on stopping the therapy, IMT needs a long-term follow-up to monitor the potential risk of loss of vision due to choroidal neovascularization, hence necessitating the distinction between these two different clinical entities. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|